Enozertinib

Overview

Enozertinib (ORIC-114) is an orally active, CNS-penetrant, highly selective and irreversible dual EGFR / HER2 inhibitor that exhibits potent and targeted inhibition of exon 20 insertion mutations . Enozertinib exhibits high kinome selectivity for the EGFR family of receptors to reduce off-target kinase liabilities. Enozertinib induces tumor regression and demonstrates antitumor activity in central nervous system and non-small cell lung cancer (NSCLC) tumor models. Enozertinib can be used for the research of solid tumors and NSCLC.

Application

Products | Products > Disease Areas > CNS Neoplasm | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > EGFR

Product Information

• Catalog No.: HY-172429
• CAS No.: 2489185-38-6
• Molecular Formula: C35H42F2N8O3
• Molecular Weight: 660.76
• Purity: 98.86%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (3.78 mM); Clear solution
• Availability: In-stock

Source

Original product source